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Abstract
The term organoid refers to a miniature version of any organ of the body. An organoid is artificially produced in vitro from stem
cells or tissue that possess the ability to recapitulate and form the three-dimensional structure of the organ they were once a part
of. Scientists have learned to create a culture for the organoid that mimics its original micro cellular environment, allowing the
3-D structure to self-organize and develop into miniature organs.The purpose of this paper is to explore the many advancements
of organoid technology, and how this progress has benefited the medical field. Organoid technology allows for the observation of
human organ development and disease, while also providing scientists with the opportunity to test drug interactions with these
“mini-organs” (Barbuzano, 2017). Organoids also shed light on the future of artificial transplantation, providing replacements
for dysfunctional organs and tissue. The advancements of organoid technology can potentially revolutionize the field of medicine,
contributing to the progress of modern biology.
Introduction
The human body is composed of a variety of tissue-specific
adult stem cell populations.Adult stem cells of each organ in
the body possess the ability to self-renew and generate all
the different cell types present in that specific organ. Recent
studies allow scientists to apply this knowledge of stem
cells by culturing them in vitro. Through growing these cells
under the right conditions, the cells can assemble miniature
versions of the organs they were once a part of (Drost &
Clevers, 2017). Through the development of new 3-D technologies and these ideas, scientists were successful in producing artificial organs like the liver, placenta, stomach, lymph
nodes, and brain. (John D. Loike and Robert Pollack, 2019).
These miniaturized models that mimic real organs have
been termed ‘organoids’ (Huch, Knoblich, Lutolf, & MartinezArias, 2017). Cells of an organoid can be derived from tissue
stem cells, embryonic stem cells or induced pluripotent
stem cells (iPSCs).These cells possess the ability to regenerate, allowing the tissue to perform its original function (Prior,
Inacio , & Huch, 2019).
The ability to create and develop human tissue in a lab
offers a major breakthrough in modern biology. The advancement of organoid formation provides scientists with
the ability to study human development and disease and
test therapeutic medicine through a personal approach.
Organoids also offer hope for transplantation of functioning organs, eliminating the need for organ donations (Huch,
Knoblich, Lutolf, & Martinez-Arias, 2017). Organoid research
can also provide improvement when it comes to animal experimentation, bioethics, and gene therapy (Xinaris, 2019).
Method
This study was written by researching peer reviewed
scholarly articles and medical journals to obtain the most
accurate information on the advancements of organoid
technology. The data was analyzed and evaluated from
many different angles, using Touro College’s access to online publications. Additional searches were done through
Google Scholar, PubMed, and the Science Journal to accumulate relevant information for the study.

Discussion
In 1998, the first successful organoid culture system derived from adult stem cells was the small intestinal organoids of a mouse. This development in organoid research
led to many discoveries, among them the knowledge
that Wnt signaling is crucial for maintaining the stem
cell compartment of the mouse small intestine. Further
observation brought about the awareness that ectopic
expression of R-spondin, which communicates with Wnt
and acts as a Lgr5 ligand, is necessary to include in a culture of intestinal stem cells as well, for ultimate function
of the organoid (Drost & Clevers, 2017).
Following these observations and through his own research, Toshiro Sato of Keio University confirmed that the
artificial inclusion of growth factors present in the organ’s
original stem cell niche is crucial for optimum efficiency and
function of the organoid. Sato too researched and studied
intestine stem cells. He observed that the 3D organoid
forms from single Lgr5-positive Intestine Stem Cells. He retained the architecture of the authentic intestine, and included Wnt/R-spondin, epidermal growth factor (EGF), noggin
(BMP inhibitor) and an artificial laminin-rich extracellular
matrix in his in vitro culture. (Drost & Clevers, 2017).
In the body, cells are exposed to intricate and complex
surroundings where they are involved in many chemical
interactions (Prior, Inacio, & Huch, 2019). When creating
an organoid derived from adult stem cells in vitro, the
stem cell niche of the specific tissue must be duplicated. Common niche factors necessary when dealing with
healthy human tissue include, but are not limited to, Wnt,
R-spondin, noggin and EGF (Drost & Clevers, 2017).
Inclusion of the precise concentrations of growth factors
within the culture, and maintaining identical micro-architecture, allows stem cells to mature into organized tissues, healthy or diseased (Dumont, Heremans, Jan et.al.
2019). Incorporating these factors in the culture will
ensure natural interactions among stem cells. It is crucial to mimic these interactions when creating in vitro
phenotypes to maintain the functions of the cells. This is
a major advancement from 2D monolayer technology to
3D technology.
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To begin creating an organoid, stem cells must be isolated from embryonic stages or adult tissues and placed into
a media with these natural growth factors. Development
begins from a totipotent cell undergoing rapid cell division. The divided cells become more restricted as they
evolve. At the blastocyst stage, the outer cells mature
into extraembryonic cells, while the inner cell mass of the
blastocyst (ICM) is composed of pluripotent cells which
possess the ability to evolve into tissue of the embryo
proper. These pluripotent cells are isolated to form the
embryonic stem cells.The next step in the developmental
process is gastrulation. During this period, cells of the
ICM mix together and perform morphogenetic movements that are controlled by signaling factors like Wnt,
fibroblast growth factor (FGF) and transforming growth
factor-beta ligands. These signaling factors activate transcription and differentiation into the three germ layers:
endoderm, mesoderm and ectoderm. After forming the
three germ layers, the progenitor cells become more
specific and form the primitive structures of organs, thus
developing into any tissues and organs of the body (Prior,
Inacio, & Huch, 2019).
Transplantation and Xenotransplantation
The development of organ transplantation (OT) is “one
of the most successful advances in modern medicine.”
For struggling patients with end stage disease, transplantation is usually their last hope to survive. One major
problem we face today regarding OT is the lack of organ
availability. We are unable to meet the exceptionally high
organ demand (Bezinover & Saner, 2019). Arthur Caplan
of NYU Langone Medical Center reports that the space
between supply and demand of transplanted organs is
“worse than it appears to be” (Caplan, 2014).
The phenomenon of creating human 3D cultures that
duplicate authentic organs allows for extensive use of
these organoids for many cell therapies, and as a potential substitute for whole-organ transplantation (Huch,
Knoblich, Lutolf, & Martinez-Arias, 2017). Organoids have
been successfully transplanted both orthotopically, in the
organs, in vivo location, and ectopically, outside of the
organ’s natural environment. Through both methods of
transplantation, organoids were successful in undergoing
cell maturation. These advancements show that organoid
models can effectively mature and develop when in contact
with natural signals provided by the in vivo environment, a
crucial understanding for developing organoid transplantation. An abundance of research in the field of organoid
transplantation is done to further advance our knowledge
of its capabilities.The use of immunocompromised mice in
many experiments has paved the way for great progress.
60

When transplanting organoids into these mice for maturation, the organoids were positioned at highly vascularized
sites, making it easier to control organoid engraftment and
growth. This allows the organoid to develop for several
months, without interfering with the mouse’s required
organ function. Some of these sites include epididymal fat
pads and underneath kidney capsules (Holloway, Capeling,
& Spence, 2019).
More recently, scientists were successful in orthotopically transplanting colonic epithelial organoids derived
from human primary tissue into the murine colon. This
study was supported by the Research Center Network
for Realization of Regenerative Medicine project from
the Japan Agency for Medical Research and Development.
The experiment was done by removal of epithelial tissue
from the mice. Results were most efficient when only
one side of the colon mucosa was removed, to prevent
obstruction of the murine colon. Following the removal
of the epithelial cells, human colon organoids were transplanted. The xenografted organoids were observed by
fluorescent endoscopic imaging. After many trials, longterm engraftment of the human colon organoids was
eventually successful and was monitored and observed
by endoscopy for over 6 months. Immunohistochemistry
of human-specific cytokeratin (KRT8/7) confirmed the
presence of the human donated epithelium in the colon
of the mouse. This study broadened our understanding of transplantation through organoids in general, but
also suggested that the location of the injury must be
significantly large to successfully create a niche for the
transplanted organoid. Small injuries requiring engrafted
tissue, although also allowing for engraftment, proved to
be more complicated. The tissue did not last as long as
the engrafted tissue of the case of the larger injury, and
eventually disappeared over time (Sugimoto, et al., 2017).
Personalized Medicine
Of the many exciting advancements brought about
through organoid research, the ability to model diseases
of specific patients in vitro can be of great benefit to medicine (Drost & Clevers, 2017). Scientists begin to predict a
future in which organoid cultures derived from a patient
can provide correct and effective therapeutic options for
that particular patient. Induced pluripotent stem cells
(iPSCs) are skin or blood cells that have been placed back
into an embryonic-like pluripotent state. This allows the
cells to mature and develop into any kind of human cell
and is commonly used for therapeutic purposes. (Huch,
Knoblich, Lutolf, & Martinez-Arias, 2017).
In regard to oncological patients, these organoids could
allow testing of drug response, minimizing the load of
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therapy. Organoids created from tumor-derived cells are
obtained from human tumor biopsies. Induced pluripotent stem cells or adult stem cells are taken from the
biopsy and develop into organoids that mimic the cancerous organs. These organoids display identical tumor
heterogeneity to their in vivo counterparts (Dumont,
Heremans, Jan et.al. 2019).
Marc van de Wetering, a senior researcher dedicated
to pediatric oncology, created a biobank of 20 tumor
organoids derived from patients with colorectal cancer
(CRC). He characterized the organoids by genes and performed drug testing to observe the correlation of specific
mutations with drug responsiveness. For example, only
one of the tumor organoid cultures reacted sensitively
to LGK974, an inhibitor of Wnt secretion. The sensitivity
toward this inhibitor was observed to be connected to
a mutation that was found in the negative Wnt regulator. This study indicated that characteristics of tumors,
histological and genetic, were mimicked precisely in the
organoid. These findings can offer a promising future in
understanding the correlation between tumor genetics
and drug response (Drost & Clevers, 2017).
Additional studies have also been done to create organoid models from normal and neoplastic murine and
human pancreas tissues. Pancreatic cancer is of the most
fatal malignancies because of its lack of improvement from
treatment and late diagnosis. Pancreatic organoids can
develop quickly from cells derived from resected tumors
and biopsies. These organoids display characteristics that
are helpful in understanding drug and therapy response of
the pancreas. Neoplastic organoids that are transplanted
back into the body, reperform the whole tumor development. The organoids develop from early-grade neoplasms into “locally invasive and metastatic carcinomas.”
Organoids are an ideal model for genetic analysis because
of their ability to be genetically duplicated. Close observation of murine pancreatic organoids presented altered
genes and pathways during the onset and progression
of the disease. After confirming these characteristics in
human tissue, organoids have been deemed as an effective
model system for discovering the nature of this deadly
malignancy (Boj, et al., 2015).
Gene Therapy
Incorporating organoids into gene-editing through the
use of tools like CRISPR/Cas9 technology offers the possibility of correcting gene mutations of patients.These repaired and healthy genes can then be transplanted into the
patient (Huch, Knoblich, Lutolf, & Martinez-Arias, 2017).
CRISPR/Cas9 also allows for manipulation of genes in organoid cultures, causing drug testing for specific genes to

be more definitive and reliable (Dumont, Heremans, Jan
et.al. 2019). Comparing a variety of organoids that are all
derived from the same iPSC line allows scientists to observe mutations in specific genes, and the effects on tissue
specification and development in organs when the genes
of a patient carry a specific congenital allele.The ability to
create organoids from the diseased tissue offers various
methods for clinicians to explore, like computerized drug
screening tests, or mirroring antibiogram tests to determine antibiotic susceptibilities (Huch, Knoblich, Lutolf, &
Martinez-Arias, 2017).
Studies were done to prove the benefits that can be
gained from adult stem cell-derived organoids with regard
to hereditary diseases (Drost & Clevers, 2017). Recently,
advancements in organoids have shown that CRISPR/
Cas9 technology can repair cystic fibrosis gene mutations
(Huch, Knoblich, Lutolf, & Martinez-Arias, 2017). Dr. J.M.
Beekman of the Regenerative Medicine Center Utrecht,
along with some colleagues, created a modeled cystic fibrosis (CF) in vitro culture. The model was composed of
cells obtained from CF patients through rectal biopsies,
creating intestinal organoids. The cystic fibrosis transmembrane conductance regulator (CFTR) gene is responsible for encoding an anion channel that is expressed
on the surface of epithelial cells. CFTR maintains fluid and
electrolyte homeostasis. Cystic fibrosis is the result of a
mutation in the CFTR gene. As a result of this mutation,
epithelial ion transport is weak, and a build-up of viscous
fluid becomes present in the respiratory and gastrointestinal tract. CFTR is activated by forskolin, which increases
intracellular cyclic AMP levels. In a healthy sample of intestinal organoids swelling was rapid. However, organoids
derived from cystic fibrosis patients presented minimal
swelling in comparison. It is now possible for researchers to test various drugs on different CF patient-derived
organoids, depending on specific CFTR mutations. These
findings shed light on a future of patient-specific treatment strategies (Drost & Clevers, 2017).
The Liver
There are many diseases associated with the liver, and
over two million deaths a year worldwide are related
to liver complications like cirrhosis, viral hepatitis and
hepatocellular carcinoma (Asrani, Devarbhavi, Eaton, &
Kamath, 2018). The amount of deaths associated with
liver disease calls for the advancement of liver organoids
as treatments for struggling patients. Researchers like
Meritxell Huch of Gurdon Institute and Takanori Takebe
from Yokohama City University present their progress in
the field of liver organoids. They were successful in creating ductal structures from adult liver and went further
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to activate these structures to differentiate into hepatocytes capable of producing bile acid and maintaining cytochrome activity (Muthuswamy, 2017).
The creation of the liver organoid has been further
developed through the use of co-culture systems. Many
studies reported that liver hepatocyte-like cells derived
from human pluripotent stem cells (hPSCs) in 2D resulted in the cells developing immaturely and did not perform
all functions of mature hepatocytes. Additionally, after
implantation of these hPSC derived hepatocyte-like cells
into immunocompromised mice, the cells operated with
little effectiveness. Due to these poor results, research
has been dedicated to creating more functional hPSC-derived hepatocytes, to produce a liver organoid model
that will function more efficiently. The use of co-cultures
is thought to be the answer to this progress. When observing mice, researchers found endothelial cells to be a
crucial cell type in the process of
liver organogenesis. Due to this finding, a hypothesis
was formed that placing endothelial cells and mesenchymal precursors with the hepatic endoderm in a co-culture will provide an environment that closely mimics in
vivo development of the liver. This will give rise to efficient hepatocyte differentiation, ultimately generating a
complex human liver bud organoid (Holloway, Capeling,
& Spence, 2019).
The liver is made up of epithelial, stromal, endothelial
and mesenchymal cells that all work together to carry
out its functions. Hepatoblasts are the embryonic progenitor cells of the liver. At the time of organogenesis, these
cells are set aside from the posterior foregut endoderm.
Hepatoblasts communicate with surrounding signaling
factors found within the mesenchyme, like FGF, BMP, hepatocyte growth factor (HGF) and Wnt. These communications cause the hepatoblasts to evolve and modify until
they can migrate into the adjacent mesoderm to form
the liver bud (Prior, Inacio, & Huch, 2019). After creation
of the hPSC-liver buds, transplantation of the liver buds
into immunocompromised mice tested the functionality
of these artificial structures. The hepatocytes of the liver
bud were proved to be functional due to the presence
of high sustained levels of albumin within the liver bud
(Holloway, Capeling, & Spence, 2019). After the liver bud
is formed, the hepatoblasts expand and differentiate to
form hepatocytes and biliary epithelium. Meanwhile, the
mesenchyme generates liver fibroblasts and stellate cells.
The structure of the liver is formed completely when the
hepatocytes and cholangiocytes mature further and the
endothelium and mesenchyme are integrated (Tremblay
& Zaret , 2005).
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Artificial Ovaries
Of all gynecological cancers, epithelial ovarian cancer
(EOC) is the fifth largest cause of cancer-related deaths in
European women. EOC patients frequently relapse, with
an expanding resistance to chemotherapy and targeted
therapy. Consequently, further research is crucial for the
advancement of therapy in EOC patients, and organoid
development seems promising. Models of EOC organoids
can contribute a constructive platform for drug testing
and screening, and can ultimately be utilized as a personalized in vitro prototype for an individual patient.
High-grade serous ovarian carcinoma (HGSOC) is a
tumor that arises from the serous tubal intraepithelial
carcinoma (Dumont, Heremans, Jan et.al. 2019). The fallopian tube epithelium (FTE) has been observed as the site
where HGSOC originates (Yucer, et al., 2017). Therefore,
observation of fallopian tube tissue can be very enlightening in discovering the nature of EOC. Mirjana Kessler of
the Department of Infectious Diseases and Respiratory
Medicine, through experimentation, created differentiated
ovarian organoids from a single fallopian epithelial stem
cell. These organoid models maintained their stability for
over several months. This experiment uncovered the existence of fallopian tube stem cells for the first time. The
creation of an ovarian organoid requires growth factors
and microcellular substances, particularly Wnt and Notch
pathways. The inclusion of Notch is especially important
because it primarily regulates and maintains the stemness
of these fallopian epithelial cells (Dumont, et al., 2019).
The urogenital system arises from the intermediate
mesoderm (IM) of a developing embryo. The Müllerian
duct within the urogenital system gives rise to the entire
female reproductive tract (Yucer, et al., 2017). Following
Kessler’s research, NurYucer of the Regenerative Medicine
Institute at Cedars-Sinai Medical Center was successful
in constructing Fallopian tube organoids (Dumont et al.,
2019). He created an in vitro culture of the Müllerian duct
from induced pluripotent stem cells.Yucer then generated
IM differentiation by adding pro-Mullerian growth factors,
causing the fallopian tube epithelium to develop. The differentiation of the cells was monitored by the addition of
cell-related markers such as PAX2, GATA3, OSR1, WT1,
and OVGP1. A 3D growth platform was set up for further
development and maturation of FTE, which successfully
caused the tissue to self-organize into an FTE organoid
structure. When forming the FTE organoid, the canonical
WNT signaling pathway proved to be crucial. Sub- set of
WNT gene family members were also included in the
culture, like WNT3a and WNT4. These genes were necessary for generating the different phases of development
and maturation of the Müllerian duct.WNT3a and WNT4
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are also responsible for inhibiting male differentiation
pathways. After three days of forming the culture, epithelial buds formed from the flat cell sheets. The buds then
became spheroids, which were put in Matrigel beads with
pro-mullerian growth factors. The intermediate mesoderm matured most at day 4, so spheroids were observed
on days 3 to 6. Inclusion of a weak estrogen, phenol red, in
Matrigel caused the complete organoid structure to form
(Yucer, et al., 2017). This finding highlights the necessity
of estrogen for the differentiating and maturing of the
Fallopian tube. To maintain and stabilize fully developed
organoids, both estrogen and progesterone must be present. (Dumont, et al., 2019) This is because estrogen alone
did not maintain the organoids for long periods of time.
More progress has been made in regard to EOC organoid
research. Dr. Oded Kopper of NewStem efficiently produced
organoids with epithelial ovarian cancer characteristics. He
obtained cells from primary tumors or metastatic lesions.
The organoids he created successfully retained identical genomic landscapes as the tumors they were derived from.
Histological aspects and heterogeneity of the tumors were
also maintained. (Dumont, et al., 2019)
Ovarian cancer organoids can be utilized to observe
various tumor responses to chemotherapy and for
drug-screening assays. Xenografting OC organoids also
allows clinicians to test drug susceptibility in vivo. These
are some of the many advancements and applications of
ovarian cancer organoids (Kopper, et al., 2019).
Another major benefit of an artificial ovary is to preserve fertility in patients suffering from cancer. An artificial
ovary can allow women to fall pregnant after the damaging effects of chemotherapy. (University of ErlangenNuremberg, 2019) Ovarian tissue cryopreservation is the
process of preserving reproductive potential in oncological
patients after being exposed to gonadotoxic therapeutic
agents. (Liverani, et al., 2019) Ovarian tissue cryopreservation involves the removal of a section or of the complete
tissue of an ovary. This tissue is then preserved for use
in the future. (Ben-Aharon, et al., 2016) Cryopreservation
can be utilized by patients with aggressive malignancies
who must receive instant gonadotoxic treatment. These
women do not have the time to receive ovulation induction, and cryopreservation can be a great benefit. Although
ovarian tissue cryopreservation can be of great assistance
for many, cancer patients with moderate-to-high risk of
ovarian metastasis are at too high of a risk. The process
of cryopreservation introduces the possibility of malignant
cells being reimplanted back into the patient.
A promising approach for these high-risk patients is
the use of artificial ovaries. Isolating follicles from a patient’s ovarian tissue and reimplanting the follicles into

an artificial ovary can guarantee that no malignant cells
will be reintroduced to the patient. (Liverani, et al., 2019)
Because follicles are isolated in a basement membrane,
there is no interaction between capillaries, follicular cells,
white blood cells and nerves.Therefore, there is no threat
that malignant cells will be introduced back to patients.
Artificial ovaries make it possible to transplant primordial and primary follicles that were isolated to survive
and could mature into follicles after transplantation. This
permits sex hormones to be secreted, regulating oocyte
maturation to the point where they are capable of fertilization. In the artificial ovary, it is essential for the follicles
to be supplied with an environment that mimics the natural human ovary. In order for the follicles to survive and
develop, interaction with the ovarian extracellular matrix
(ECM), as well as surrounding ovarian cells must be present. For example, ovarian stromal cells are required to
activate primordial follicles, while endothelial cells are
necessary for vascularization, providing transportation
of oxygen and nutrients, paracrine factors, and removal
of metabolic waste. The presence of the ovarian ECM is
responsible for maintaining 3D follicle structure, as well
as other important roles.Therefore, all these factors must
be present. (Dolmans & Amorim, 2019)
Drs.Teresa Woodruff and Ramille Shah of Northwestern
University led a team of scientists in creating artificial ovary structures. The process utilized a 3D printer
to create the structure that would hold the follicles. A
stainless steel nozzle was used for the printer, which was
around the width of a strand of hair. Five layers of gelatin
filaments were printed at various angles. Tiny cylinders
were punched through the sheets, creating pores to hold
mice follicles. Nine mice were involved in the study, and
all ovaries were removed. Seven of the mice received the
structures with the follicles, and two received the artificial structures without follicles. Following the mating
of these mice with male mice, three mice with artificial
ovaries produced litters. The artificial ovaries also joined
with the blood vessels of the mice, allowing for female
hormones involved in milk production to be made. The
hormones successfully traveled the mouse bloodstream
to the breast tissue where it stimulated milk production
(Piazza, 2018). The ability of an artificial ovary to restore
endocrine function and provide an environment for follicular development can be extremely useful for oncological
patients in the future (Cho, Kim, Noh, & Ku, 2019).
Virology
The coronavirus disease-19 (COVID-19), caused by the
SARS-CoV-2 virus is responsible for over 250,000 deaths
globally. (Han, et al., 2020) The COVID-19 pandemic
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proved to the world just how threatening newly surfacing
viruses can be. Understanding the nature of these viruses
rests in the use of in vitro cultures capable of viral replication. The use of organoids is now demonstrating its
practicality when experimenting the tendencies of these
deadly viruses.
The novel coronavirus first infected humans in
December of 2019. Various research groups have been
experimenting with organoids to better understand the
nature and tissue tropism of SARS-CoV-2. Josef Penninger
of the Institute of Molecular Biotechnology, along with
his colleagues, created capillary and kidney organoids,
both derived from human iPSCs. Through this research,
Penninger proved that SARS-CoV-2 can infect both sites
in the body.These observations help explain the ability of
the virus to spread throughout the body and the damaging effects on kidney function in infected individuals.
Multiple studies were done to establish whether the
virus can infect the gastrointestinal tract. Intestinal organoids derived from adult stem cells were examined and
presented high levels of angiotensin converting enzyme 2
(ACE2), a receptor for SARS. The studies displayed that
enterocytes, the most common intestinal epithelium cell
type, were infected with the virus. These findings verified
that the intestine is a potential site for SARS-CoV-2 infection (Clevers, 2020).
Mart Lamers of Erasmus Medical Center, along with his
colleagues, further investigated the ability of SARS-CoV-2
to infect the intestines. The human small intestine epithelium is composed of multiple cell types. The experiment
consisted of 3D structures that displayed all cell types,
grown in four separate cultures. Each culture displayed
different amounts of ACE2, proving their ability to be
infected with SARS-CoV-2. Through the use of electron
microscopy, Lamers and his colleagues observed that the
virus caused infection in mature and progenitor enterocytes alike. This study suggests that the use of human
organoid models can provide researchers with beneficial
resources for examining the nature of SARS-CoV-2 and
other coronaviruses. (Aaas, 2020)
Since the primary infection site for SARS-CoV-2 is in
the respiratory organs, research was done to create a
lung organoid derived from human pluripotent stem cells
(hPSCs). Development began with the differentiation of
the hPSCs into definitive endoderm. The cells then further progressed into the anterior foregut endoderm
(AFE) and formed AFE/lung progenitor cells. Further
specification and maturation of these cells eventually
formed the lung organoids. The ability of these lung organoids to provide a platform for modeling COVID-19
was then put to the test. The cultures were introduced
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to the SARS-CoV-2 virus, and after 24 hours viral RNA
was detected. The use of immunostaining proved the
presence of SARS-S protein in the lung organoids. Based
on this research, scientists can utilize these organoids to
observe the effects of various drugs on the coronavirus,
by observing any decrease in the amount of markers
present from the injected virus. (Han, et al., 2020)
Conclusion
Organoids possess the ability to model tissue structure
and function with great accuracy, but more research is
required to take full advantage of organoids. Organoids
still lack vasculature, immune cells, and other cellular
components that tissues communicate with and depend
on in the body (Iakobachvili & Peters, 2017). Without all
the essential cellular components of an organ, the use
of organoid in human transplantation will be limited.
Studying processes where these components are necessary is therefore limited. (Souza, 2018) Efforts to improve
the vasculature of organoids will provide nutrient supply,
excretion of toxins and signaling that is present in the
body. This research is presently making progress, though
it is demanding and yet to be fully incorporated into standard tissue culture facilities. (Iakobachvili & Peters, 2017)
Organoid technology brings up many ethical questions
as well. For example, what might happen if scientists can
successfully create a brain organoid? Utilizing a brain organoid for drug testing would be helpful, but it may pose
an ethical issue to transplant this organoid into a patient.
These matters must be addressed in the future. However,
we do know that organoid technology is adding a whole
new dimension to the medical field.
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